Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“NANETS 2026 Update: What has changed in Stage I–III Rectal NETs?
The paradigm is shifting:
- Less radical surgery.
- More personalized staging.
- Greater rectal preservation.
Key messages from the guideline:
- >90% show indolent behavior.
- More accurate nodal staging with 68Ga- or 64Cu-DOTATATE SSTR PET/CT.
- Tumor size and grade remain core risk drivers.
- 11-20 mm – higher LN metastasis risk.
- >20 mm – surgery remains standard.
For lesions ≤20 mm: Advanced endoscopic techniques (mEMR, ESD, EFTR) enable minimally invasive excision, with oncologic outcomes approaching surgery and improved quality of life.”
Title: Bridging the Gap: Transforming Total Neoadjuvant Therapy: NEOTERIC Signals a Step Forward in the Treatment of Locally Advanced Rectal Cancer
Authors: Christopher G. Cann, Cathy Eng, Ramya Thota
Read The Full Article
Other articles featuring Ahmet Dirican on OncoDaily.